Clinical effect of azelastine and budesonide nasal sprays in adult patients with persistent allergic rhinitis

Objective To evaluate the clinical effect of azelastine hydrochloride and budesonide nasal spray in the quality of life( QOL) in adult patients with persistent allergic rhinitis( AR). Methods One hundred fourty-eight patients with persistent AR were randomly divided into treatment group( n = 50),control group( n = 50) and placebo group( n = 48). Treatment group was treated with azelastine hydrochloride nasal spray,one spray for each side of the nasal cavity in each morning and night,per spray was 0. 14 mg. Control group was treated with budesonide nasal spray,two sprays for each side of the nasal cavity in each morning,per spray was 64 μg. Placebo group was treated with 0. 9%Na Cl,two sprays for each side of the nasal cavity in each morning. Three groups were continued medication for 4 weeks. Comparison of nasal symptoms and quality of life in three groups by nasal symptom score,the MOS item from health survey( SF-36) and rhinoconjunctivitis related quality of life questionnaire( RQLQ). Results In the azelastine hydrochloride and budesonide groups,after 4-weeku0027 s treatment,nasal symptom scores,SF-36 scores and RQLQ scores were significantlyimproved in comparison with the placebo group( P 0. 05). Budesonide treatment for 4 weeks resulted in a significant improvement in nasal symptom scores,SF-36 scores and RQLQ scores than azelastine hydrochloride( P 0. 05).Conclusion Our findings suggested that both azelastine hydrochloride and budesonide nasal spray can significantly improve quality of life in the treatment of adult patients with persistent AR. Moreover,this comparative provided the evidence that budesonide nasal spray is superior to azelastine hydrochloride nasal spray in improving quality of life of persistent AR patients.